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Abstract 
The main objective of the study was to identify factors that affect survival of HIV/HBV co-
infected patients. The study used data from TASO Uganda. Patients who registered with the 
organization between 2005 and 2010 were followed to determine their survival. The covariates 
of study were age, education level, number of sex partners, Disease stage, weight, HBV related 
condition, being on ARV’s. To estimate the survival function for every subgroup of each 
variable, the product- limit method developed by Kaplan and Meier was used (Kaplan and Meier, 
1958) and a log rank test to compare the survivorship functions across several groups. Lastly,a 
proportional hazards model was used to examine the joint effect of the covariates on the duration 
of survival assuming a Gompertz distribution for the time variable. The study revealed the 
duration of survival for HIV/HBV co-infected patients increased with increasing weight. Patients 
who had Hepatocellular carcinoma or Cirrhosis at diagnosis were at an increased risk of death as 
compared to those who had chronic active hepatitis B. Patients on ARVs had an increased death 
rate as compared to those who were not on ARVs, because the study showed that majority of the 
Patients seek for treatment when they are infected with Carcinoma, the old stage of Hepatitis B. 
Given the fact that ARVs have been thought to make life better for HIV/AIDS patients, there is 
need for further research in this area. Patients who were educated had a reduced death rate as 
compared to the uneducated ones. Therefore, emphasis should be on designing Information 
Education Communication (IEC) materials to sensitize the uneducated HIV/HBV co-infected 
patients on effects of non compliance and unbalanced diets. 
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Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. Hepatitis B 
is an infectious hepatitis caused by the hepatitis B virus (HBV). This infection has two possible 
phases; acute and chronic (Bonacini & Kurz, 2002).  Acute hepatitis B refers to newly acquired 
infections; affected individuals notice symptoms approximately 1 to 4 months after exposure to 
the virus.  Most people with acute hepatitis, symptoms resolve over weeks to months and they 
are cured of the infection. However, a number of people develop a very severe, life-threatening 
form of acute hepatitis called fulminant hepatitis. Chronic hepatitis B is an infection with HBV 
that lasts longer than 6 months. Once the infection becomes chronic, it may never go away 
completely (Bonacini  & Kurz,   2002).  
 
Approximately 90 to 95 percent of infected adults are able to fight off the virus so their infection 
is cured. Only about 5 to 10 percent of adults infected with HBV go on to develop chronic 
infection, and children are at much higher risk for chronic infection (Hoffmann & Thio, 1990).  
Studies have shown that up to 90 percent of infected young children will fail to clear the virus 
from their bodies and go on to develop chronic infection. About two-thirds of people with 
chronic HBV infection are chronic carriers. These people do not develop symptoms, even though 
they harbour the virus and can transmit it to other people. The remaining one third develop 
"active" hepatitis, a disease of the liver that can be very serious (Hoffmann, & Thio, 1990).   
 
It is realized that the liver is an important organ that filters toxins out of the blood, stores energy 
for later use, helps with digestion, and makes substances that fight infections and control 
bleeding, and this liver has an incredible ability to heal itself, but long-term inflammation caused 
by HBV can result in permanent damage. Scarring of the liver is called cirrhosis, a condition 
traditionally associated with alcoholism but one that is also caused by chronic active hepatitis B 
infection. When this occurs, the liver can no longer carry out its normal functions and may fail 
completely. The only treatment for liver failure is liver transplant. According to WHO, (2004) 
report about 15 to 25 percent of people with chronic hepatitis B die of liver disease. 
 
According to WHO (2006), people who are at an increased risk of being infected with the 
hepatitis B virus include : Men or women who have multiple sex partners, especially if they don't 
use a condom, Men who have sex with men , Men or women who have sex with a person 
infected with hepatitis B virus, People with other sexually transmitted diseases, People who 
inject drugs with shared needles, People who receive transfusions of blood or blood products, 
People who undergo dialysis for kidney disease, Institutionalized mentally handicapped people 
and their attendants, caregivers, and family members ,Health care workers who are stuck with 
needles or other sharp instruments contaminated with infected blood, Infants born to infected 
mothers 
 
For those who do get sick, symptoms usually develop within 1 to 4 months after exposure to the 
virus. The initial symptoms are often similar to the flu. Common symptoms of hepatitis B 
include: Appetite loss, feeling tired (fatigue), nausea and vomiting, itching all over the body, 
pain over the location of the liver (on the right side of the abdomen, under the lower rib cage), 
Jaundice (a condition in which the skin and the whites of the eyes turn yellow in color), dark 
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urine (the color of cola or tea). Hepatitis B is among the causes of global mortality. It is spread as 
HIV an infectious killer of adults. 
 
Infection with Hepatitis B is one of the common human infections worldwide. The association 
between Hepatitis B and HIV presents an immediate and grave public health and socioeconomic 
threat, particularly in the developing world. The impact of the two viral infections on resource-
poor countries have ominous social and medical implications, and the already overstretched 
health services now have to face a tremendously increasing Hepatitis B problem (Hudson et al, 
1988). HIV infection worsens the situation by increasing reactivation of chronic Hepatitis B 
infection in dually infected persons as well as favoring rapid progression of new infections in the 
HIV-infected. This also results in an increase of the risk of infection and a subsequent increase of 
cases in the general population (Hoffmann et al,1990). 
 
The risk of death from Hepatitis B in Uganda has increased especially among HIV/HBV co-
infected patients despite good clinical and microbiological response to Pegylated interferon alfa-
2b Pegasys ( Lalla et al, 1990 ; Hudson et al, 1988). The risk factors for this increased hepatitis B 
associated mortality however need to be studied further in Uganda, because they are important in 
improving treatment outcome among such patients.  
 
The study was guide by the main objective to determine the factors associated with survival of 
HIV/HBV co-infected patients. The following hypotheses were tested: The survival of HIV/HBV 
co-infected patients is independent of socio demographic factors (age, number of sex partners, 
Education level, marital status) of the individual, and the survival of HIV/HBV co-infected 
patients is independent of clinical factors (HBV related conditions, ARVs, weight, WHO stage). 
 
2. Literature Review 
Hepatitis B is the most common serious liver infection in the world. Worldwide, an estimated 
two billion people have been infected with the hepatitis B virus (HBV), and more than 350 
million have chronic (long-term) liver infections, of whom, more than 620,000 die from liver-
related disease each year (WHO, 2004). 
 
In the United States, hepatitis B is largely a disease of young adults aged 20-50 years. About 
800,000 to 1.4 million Americans are chronic hepatitis B virus carriers, and the disease causes 
about 3, 000 deaths each year (Hudson et al, 1988). The good news is that infection with HBV is 
usually preventable because there is an effective vaccine. Use of the vaccine has resulted in an 
82 percent decrease in the number of new infections reported in the United States each year.  
 
The problem of Hepatitis B and its related conditons in any country has been responsible for 
much of the deaths especially among people with HIV/AIDS and therefore the study to find out 
the factors associated with the survival of people co-infected with HIV/AIDS and HBV was 
inevitable. Globally, 600,000 were the estimated deaths (in 2002), 70% estimated HepB3 
coverage and 92% of the countries integrated HepB in routine immunization (WHO, 2004). 
 
According to the AMREF (1999), while there are around 25 million HIV-infected persons in 
sub-Saharan Africa, there are also an estimated 50 million with chronic hepatitis B virus (HBV) 
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infection.  The scale-up of' HIV treatment with antiretroviral medication (ARVs) in Africa 
should result in substantial reductions in morbidity and mortality. In developed countries, 
however, improved survival with highly active antiretroviral therapy (HAART) has been 
associated with notable increases in mortality due to liver disease among HIV-infected persons. 
Also, persons co-infected with hepatitis viruses have significantly higher liver-related toxicity 
with ARVs compared to persons infected with HIV alone as well as protocol investigated 
predictors of liver disease among co-infected participants (Feld et al, 2005). 
 
Hepatitis and HIV have been closely linked since the emergence of AIDS. HIV infection has 
contributed to a significant increase in the worldwide incidence of Hepatitis B (UNAIDS, 1996). 
About 25 million people in sub-Saharan Africa are infected with HIV and about 50 million with 
chronic HBV, and patients with both viruses face a dreadful progressive decline in cell-mediated 
immunity, this greatly increases the risk of developing liver related diseases in co-infected 
individuals and leading to more frequent deaths involvement and atypical radiographic 
manifestations. It is further observed that although some HIV-related infections are both 
treatable and preventable, incidence rates continue to rise in developing nations where HIV 
infection and Hepatitis B are endemic and resources limited like Uganda.  
 
According to Feld et al. (2005), globally Hepatitis is among the most common opportunistic 
infection affecting HIV-seropositive individuals and it is the most common cause of death in 
patients with AIDS and Hepatitis B virus (HBV) being the leading cause of chronic liver disease 
and liver-related death worldwide, with the majority of these cases occurring in areas of Africa 
and Asia where HBV prevalence is high. Many of the countries that are affected by hepatitis B 
are also affected by a high HIV burden, leading to frequent HIV/HBV co-infection. The 
consequences of co-infection, including increased liver-related morbidity and mortality, 
increased hepatitis B viral replication, immune reconstitution to HBV in the setting of 
antiretroviral therapy, and hepatotoxicity from antiretroviral drugs, are especially important in 
regions with expanding antiretroviral programmes. (Hoffmann et al, 1999). It is further noted 
that in some areas of sub-Saharan Africa, the rates of co-infection exceed 1,000 per 100,000 
population (Dye et al, 1999). They observed that Hepatitis B case rates have increased in sub-
Saharan Africa since 1985. It is argued that these increases were relatively greater as HIV 
seroprevalence increased. 
 
According to WHO (2006), a person who is HIV-positive and infected with Hepatitis B virus has 
a very high likelihood to become sick with chronic Hepatitis B than someone infected with 
Hepatitis B virus who is HIV-negative (Moore  et al, 1988). Co-infections accounts for about 13 
percent of AIDS deaths worldwide. The report further indicated that in Africa, HIV is the single 
most important factor determining the increased incidence of Hepatitis B. It is common to find a 
patient with HIV having Hepatitis B in Uganda (Bwogi et al, 2009). Such a situation lowers the 
immunity of that patient and makes him vulnerable to other opportunistic infections, which 
required a study to find out the factors associated with the survival of Hepatitis B and HIV co-
infected patients so that they can be mitigated.   
 
ART in HIV-Hepatitis B patients; In a study that was done to assess the Liver in HIV in 
Africa, it was noted that as access to antiretroviral therapy improves across the African continent, 
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liver disease is emerging as an important cause of morbidity and mortality among HIV-infected 
individuals. Although coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV), 
along with highly active antiretroviral therapy (HAART)-induced hepatotoxicity appear to be the 
major causes of liver disease in this population, other diseases endemic to Africa with hepatic 
manifestations are influenced by HIV infection  (Feld et al, 2005).  
 
Feld  et al. (2005) noted that although highly effective therapy exists for both HIV and HBV, 
concomitant administration is fraught with difficulties. Problems arise when giving these 
therapies concomitantly and many physicians delay highly active antiretroviral therapy 
(HAART) for two or more months to minimize the risk of toxic side effects. It is known that 
patients with low CD4 counts are at increased risk of progression and mortality, and are also 
more prone to side effects and toxicity from therapy.  
 
Sex differences and Hepatitis B; According to WHO (2002) report, Hepatitis B and Tuberculosis 
is responsible for more female deaths around the world than any other infectious disease. The 
report further indicates that worldwide apart from TB, Hepatitis B is also a single killer of young 
women; causing maternal mortality in developing countries to increase. 
 
In a study that was done in Africa by Bwogi et al, (2003) , it was found out that gender related 
differences at presentation existed and one-year outcomes after the initiation of HBV treatment 
showed no difference in survival. Also, Hepatitis B virus (HBV) is the leading cause of chronic 
liver disease and liver-related death worldwide, with the majority of these cases occurring in 
areas of Africa and Asia where HBV prevalence is high. Many of the countries that are affected 
by hepatitis B are also affected by a high HIV burden, leading to frequent HIV/HBV co-
infection.  
 
The consequences of co-infection, including increased liver-related morbidity and mortality, 
increased hepatitis B viral replication, immune reconstitution to HBV in the setting of 
antiretroviral therapy, and hepatotoxicity from antiretroviral drugs, are especially important in 
regions with expanding antiretroviral programmes. Little data, however, are available on 
HIV/HBV co-infection from regions with high chronic hepatitis B prevalence. However, in a 
prospective study that was carried out to determine treatment outcome in an unselected cohort of 
HBV patients admitted at Children's Hospital Boston and Zomba General Hospital in Malawi, 
death rates were similar in men and women (Harries et al, 1998). Although WHO (2002) and 
Bwogi et al. (2003) indicated a difference in survival based on sex, the study by Harris et al. 
(1998) did not show any differences in survival of the patients based on sex. Therefore it 
remained unclear whether sex is a factor that influenced the survival of HIV-HBV co-infected 
patients that this study intended to find out.   




Site of disease and survival; Mcmahon et al. (1990) have shown that survival time of HIV-HBV 
co-infected patients is associated with the site of HBV disease. In their study using the log rank 
test, the median survival was shortest in patients with both hepatocellular carcinoma and 
cirrhosis, followed by those who had active hepatitis B alone and then those who had only URTI. 
In a proportional hazards regression analysis, which adjusted for CD4+ count, hepatocellular 
carcinoma disease was among the factors independently associated with shorter survival. 
 
Giovanni et al, (2003) concluded that the site of HBV had no significant influence on the 
survival of the HIV HBV co-infected patients and therefore, there were no differences in survival 
of the patients who had active hepatitis B and those who had URTI. They used the Kaplan-Meier 
technique and the generalised log-rank test to construct and compare the survival probabilities 
curves of the two groups. This was also a concern for the researcher in this study to find out 
whether site of the URTI had an influence on the survival of the HBV and HIV co-infected 
patients. 
 
Hepatitis B related condition; Hepatocellular carcinoma (HCC, also called malignant hepatoma) 
is a primary malignancy (cancer) of the liver. Cirrhosis is a consequence of chronic liver disease 
characterized by replacement of liver tissue by fibrosis, scar tissue and regenerative nodules 
(lumps that occur as a result of a process in which damaged tissue is regenerated), leading to loss 
of liver function. Cirrhosis is most commonly caused by alcoholism, hepatitis B and C, and fatty 
liver disease, but has many other possible causes. Glomerulosclerosis is Inflammation of the 
glomeruli, caused often by an autoimmune disease, but it can also result from infection, and the 
most common signs of glomerulosclerosis are proteinuna and kidney failure. USAID,(2006) and 
Feld et al(2005). 
 
3. Methodology 
This section shows data source, study participants, data processing and analysis. The data used in 
this study was from records of HIV/HBV patients registered with TASO Uganda. Patients who 
were considered in this study are those registered between April 2005 and June 2010 and had 
been on treatment for at least 60 days. Time from the date of enrollment to the date of death or 
censoring was taken as the response variable for survival analysis.  The covariates of interest  
included; age, number of sex partners, marital status, education level, occupation, ethnic group, 
HB related condition, weight, Disease stage and being on ARVs. The Study participants were all 
TASO clients who were HIV/HBV infected, attending TASO between April 2005 and June 
2010. 
 
Raw data was received from TASO in Microsoft Access and then was exported from Access to 
STATA for analysis. Data was declared as survival data with death as the failure variable and the 
time from the enrollment to death/censoring as the time variable. To achieve the desired 
objectives, different methods of data analysis were employed. These included description of the 
variables used in the study in form of frequency tables, examination of the relationship of 
individual variables with time to death and model estimation (multivariate survival analysis).  
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Descriptive statistics were used to summarize characteristics of the study population. Continuous 
and discrete variables were summarized into standard deviations, modes, ranges, medians, and 
means. Nominal and ordinal variables were summarized into frequencies, percentages and 
medians, and confidence intervals presented. 
Examining the individual relationship of each variable to survival, and estimating the survival 
function for every subgroup of each variable, the product- limit method developed by Kaplan 
and Meier was used (Kaplan and Meier, 1958). The product- limit method estimates the 
survivorship function, S(tj) at time tj, which is the probability of surviving up to the time tj. The 





















Where jt  is the time of the j
th death 
ir  is the number at risk at time it  
id  is the number dying at time it  
To compare the survivorship functions across several groups, the log rank test was used.  The log 
rank test is based on a set of scores (Wi) assigned to the observation.  The scores are functions of 













Where mj is the number of failure times.  
rj is the number at risk. 
















The log rank test depends solely on the sum S of the W scores in any of the groups. 


























Where n1 is the number of observations in group 1 
n2 is number of observation in group 2 
k is number of distinct failure times (Lee, 1992) 
Therefore the log rank test statistic, L, is represented as 







which follows an asymptotically standard normal distribution under the null hypothesis.   
The test statistic, L, has a critical region L<Z if S is obtained from group 1 and L>Z otherwise.   
 
The Nelson-Aalen estimator due to Nelson (1972) and Aalen (1978) was employed to estimate 
the cumulative hazard functions for different group variables instead of survivor functions 
(Kaplan-Meier estimators). The Nelson-Aalen estimator has better small-sample properties than 












Where nj is the number at risk at time tj, dj is the number of failures at time tj, and the sum is over 
all distinct failure times less than or equal to t. 






















t  …………………………………………………….(3.7) 
Estimates the asymptotic variance of ln )(ˆ tH and 2/z is the (1- 2/ ) quantile of the normal 
distribution. 
 
Theoretically, the survival and cumulative hazard functions are related by 
S(t) = exp{-H(t)} 
or        H(t) = -ln{S(t)}…………………………………………………..........(3.8) 
 
Klein and Moeschberger (2003) observed that for survival function and cumulative hazard 
function, both the Kaplan-Meier estimator and the Nelson-Aalen estimator are consistent 
estimates. These statistics are asymptotically equivalent. Also according to Hosmer and 
Lemeshow (1999), the Nelson-Aalen estimator of the survival function is always greater than or 
equal to the Kaplan-Meier estimator. However, the Kaplan-Meier estimator has   a shortcoming 
that once the estimator is zero, it remains zero regardless of future activity.  The Nelson-Aalen 
estimator does not suffer from this problem, since it will increase with every failure event, even 
after the Kaplan-Meier estimate would have reached zero.   
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Multivariate analysis was performed to determine the factors associated with the survival time of 
the patients. A proportional hazard model was fitted. 
The proportional hazard model is of the form; 
)exp()()|( 0 xjj thth βxx  ………………………………………………………(3.9) 
Where ho(t) is the baseline hazard function, 
Xjs are the covariates, 
t is time to death of an individual. 
 
Different proportional hazard models were fitted assuming three distributions of the survival 
time. The three distributions considered were the exponential, Weibull and Gompertz. The 
hazard functions of these distributions are the following: 
 
Exponential: h(t) = , >0………………………………………………….…..(3.10) 
Weibull: h(t) = t-1, >0………………………………………………….(3.11) 
Gompertz: h(t) = exp( + t)……….………………………………………….(3.12) 
 
The best fit among the three distributions was selected by comparing the AIC values of the 
observed data under the three distributions.  
 
AIC = 2k -2(log likelihood) ……………………………………………………….. (3.13) 
Where k is the number of free parameters in the model. The model with the minimum AIC value 
was chosen as the best model to fit the data (Akaike,1973). 
4. Findings of the Study 
This section presents the results of the analysis as described in chapter three. It tries to explain 
the factors associated with survival of HIV/HBV co-infected Patients. The characteristics of the 
patients considered were grouped into socio-demographic age, sex, marital status, Education, 
occupation and number of sex partners. It further presented the clinical factors for the patients at 
baseline. 
 
A total of 347 Patients were included in this study, of these there were more females 53.5 percent 
compared to males. Many patients were married 47.8 percent and a small number had never 
married 3.6 percent. The study further indicated that 61.4 percent attained primary school 
education. At least 23.6 percent attained secondary school education and only 11.8 percent had 
no formal education. The mean age of the patients was 37 years. The minimum age being 23 
years and maximum 71 years. Most of the patients in the study were aged above 40 years 43.2 
percent. The study further showed that 74.2 percent of the patients had atleast 2 sexual partners, 
only 25.8 percent had atmost 1 partner. 
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Table 4.1: Distribution of HIV/HBV patients by socio-demographic characteristics  
Variable Number Percentage 
Sex      
Female  186 53.5 
Male  161 46.5 
Total  347 100.0 
Age group (years)    
20-29 72 20.7 
30-39  125 36.1 
>=40  150 43.2 
Total  347 100.0 
Marital status   
Never married 12 3.6 
Married 166 47.8 
Divorced/Separated 101 29.0 
Widowed 68 19.6 
Total  347 100.0 
Education level     
None 41 11.8 
Primary 213 61.4 
Secondary  82 23.6 
Tertiary 11 3.2 
Total  347 100.0 
Occupation    
None 77 22.1 
Paid employee 93 26.8 
Peasant 107 30.7 
Other 70 20.4 
Total  347 100.0 
Number of sex partners    
At most 1 90 25.8 
At least 2 257 74.2 
Total  347 100.0 
 
Most of the patients were not on ARVs (80.1%) at baseline. Information on Disease stage of HIV 
reveals that three quarters of the patients (76.2%) were in stage III (immunity is compromised 
and opportunistic infections are rampant like HIV/AIDS), 14.7 percent were in stage II and only 
9.1 percent were in stage IV. The results further show that most of the cases had Hepatocellular 
Carcinoma (53.7%) and a few patients had Cirrhosis (7.4 %). The mean weight of the patients 
was about 51kg. The minimum weight of the patients was 29kg and the maximum was 90kg. 









Table 4.2: Distribution of HIV/HBVpatients by baseline clinical conditions 
Variable Number Percentage 
Weight (kg)   
< 50  165 47.5 
>= 50  182 52.5 
Total 347 100.0 
ARVs   
No 278 80.1 
Yes 69 19.9 
Total 347 100.0 
Disease stage   
II 51 14.7 
III 264 76.2 
IV 32 9.1 
Total  347 100.0 
HBV related condition   
Chronic active hepatitis 75 21.7 
Hepatocellular Carcinoma(HCC) 186 53.7 
Cirrhosis 27 7.4 
Urinary Track Infections(URTI) 59 17.2 
   
Total  347 100.0 
 
 
Using Kaplan-Meier survival time analysis and the log rank test methods, the results of the 
relationship of individual variables with time to death were presented as shown in the tables 
below. The tables displayed the number and percentage of failures and the mean survival time 
for different covariates, that is, sex, age, marital status, education level, occupation, number of 
sex partners, HBV related condition, weight, Disease stage and ARVs. In addition, the tables 
displayed the value of the log-rank statistic and its level of significance used to assess the 
differences in the survival functions of selected variables across the levels of particular variables.  
 
It was observed that survival was different across different categories of marital status (p=0.02.). 
The marital status of a patient seemed to significantly affect the duration of survival. It can be 
observed that widowed patients had the highest proportion failure, followed by the 
divorced/separated. It is also surprising that the never married had the least failure time. The 
table further shows that survival was different across different levels of education (p=0.05). The 
level of education of a patient seemed to affect the duration of survival. Furthermore, the number 
of sex partners had a significant effect on the duration of survival (p=0.01). 
 
Survival time was not significantly different across different categories of sex, age group and 
occupation of HIV/HBV co infected patients (p>0.05). This implies that these factors seemed not 
to affect the duration of survival for HIV/HBV co infected patients. 
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Sex     0.07 0.79 
Female  186 10 5.4 1098   
Male  161 9 5.6 864   
Age group     2.76 0.25 
20-29 72 4 5.6 1076   
30-39  125 6 4.8 915   
>=40  150 11 7.3 1080   
Marital status     9.95 0.02 
Never married 12 1 8.3 821   
Married 166 11 6.6 909   
Divorced/Separated 101 13 12.9 1079   
Widowed 68 18 26.5 1051   
Education level     7.81 0.05 
None 41 4 9.8 1041   
Primary 213 12 5.6 1072   
Secondary  82 3 3.7 912   
Tertiary 11 1 9.1 857   
Occupation     2.38 0.50 
None 77 5 6.5 1073   
Paid employee 93 6 6.5 909   
Peasant 107 7 6.5 1106   
Other 70 6 8.6 858   
Number of sex 
partners   
  
  
At most 1 90 6 6.7 1093 1.03 0.01 
At least 2 257 72 28.0 848   
       
 
Survival time was found not to be different by gender of patient, age group and occupation at 5 
percent level of significant (P-values>0.05). This is in agreement with Harries et al, (1998) 
whose study on HBV patients admitted at Children’s hospital Boston and Zomba General 
hospital in Malawi, death rates were simillar in men and women, hence more research needed. 
 
The time to death for HIV/HBV co-infected patients depended on someone’s weight (p=0.01). 
Weight was categorized into two groups that is, those below 50kg and those who were 50kg and 
above.  The survival time increased with increase in weight. It is also evident that survival was 
different among those patients who were on ARVs and those who were not (p=0.03). The mean 
survival time was higher among those who were not on ARVs as compared to those who were on 
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ARVs. The baseline HBV related condition of the patients seemed to have a significant effect on 
their survival (p=0.04). Those ones who had chronic active hepatitis had a longer mean survival 
time (1107days) as compared to the rest, as was studied by Jordan et al,(2005). 
 
Generally, patients who were in Disease stage II had a longer mean survival time (1110days) as 
compared to those who were in Disease stage III and IV. However, the baseline Disease stage 
seemed not to have a significant effect on the survival of HIV/HBV co-infected patients 
(p=0.19). 
 











Weight     5.96 0.01 
< 50  165 14 8.5 885   
>= 50  182 8 4.4 1114   
ARVs     4.72 0.03 
No 278 16 5.8 1105   
Yes 69 6 8.7 872   
Disease stage     3.28 0.19 
II 51 1 2.0 1110   
III 264 20 7.6 1088   
IV 32 2 6.3 910   
HBV related 
condition   
  
10.17 0.04 
Chronic active hepatitis 75 4 5.3 1107   
Hepatocellular 




796   
Cirrhosis 27 2 7.4 819   
URTI 59 3 5.1 898   
       
 
Nelson-Aalen estimator was also employed to give the visual picture of cumulative hazard 
functions of different variables under different categories.  
 
Hazard estimate by Sex; It was observed that though the cumulative hazard functions 
converged at the beginning of the analysis time, females had a lower hazard than males. This 
implies that females took longer to die as compared to males.  
 




Figure 4.1: Nelson-Aalen cumulative hazard estimates by sex 
The hazard estimate by age increased with increasing age at the beginning . As time went on, the 
hazard for those aged 30-39 years decreased and then stabilized. Then the hazard for the ones 
aged 20-29 years increased and later stabilized. The hazard continued to increase among the 
older patients (>= 40years) but stabilized at the end. Old patients who were aged 40 years and 
above had a higher hazard as compared to the rest. The hazard was highest for patients who were 
widowed and lowest for those who were married. This implies that married take longer to die 







0 500 1000 1500 
days 
































0 500 1000 1500 
days 

























0 500 1000 1500 
days 
 Never married  Married 





































African Journal of Economic Review, Volume IV, Issue 2, July 2016 
162 
 
Figure 4.3: Nelson-Aalen cumulative hazard estimates by marital status 
The hazard was highest among those patients with no formal education as compared to those 










It is observed that patients with baseline weight of greater than or equal to  
Figure 4.4: Nelson-Aalen cumulative hazard estimates by education level 
 
50kg had their hazard lower than that of patients with a lower weight. Also, HIV/HBV co-
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Figure 4.5 Nelson-Aalen cumulative hazard estimates by weight 
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The hazard was highest among patients who were in WHO stage III and was lowest among those 
who were in WHO stage II. It is also observed that at the beginning of the analysis time, patients 
with hepatocellular carcinoma had a higher hazard than the other patients who had other baseline 
HBV related conditions but as time went on, their hazard became constant and those ones who 













Figure 4.7 Nelson-Aalen cumulative hazard estimates by Disease stage 
Using the log rank test to test for equality of survival functions, weight, being on ARVs, HBV 
related condition, education level and marital status were found to significantly affect survival. A 
Gompertz proportional hazards model, which had the minimum AIC value, was considered as 
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Table 4.4: Estimated Gompertz proportional hazards model   
Number of observations = 747                                                LR 
2  (12)   = 30.42 
Log likelihood =   -209.74796                              Probability > 
2      = 0.0024 
Variable Hazard. 
Ratio    
Standard 
error 
P 95% Confidence Interval 
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0.270              1.153 
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0.160             1.594 
0.174             1.809 
0.358             3.347 
HBV related condition 
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0.888              5.258  
0.289              5.161 
0.587              3.103 
* * Significant at 5%   * Significant at 10% 
 
The weight of patients was significantly associated with survival after controlling for other 
factors. A one-kilogram increase in weight reduced the hazard by 4 percent. The survival of the 
patients increased with increasing weight. This is because massive loss of weight is a sign of lost 
immunity which comes as a result of increased viral load hence a result of reduction in the CD4 
count, and an individual is prone to opportunistic liver infections. Massive loss of weight can be 
used to predict time to death. Being on ARVs was seen to be significantly associated with the 
survival of HIV/HBV co-infected patients after adjusting for other factors (p=0.046). The hazard 
increased by 96 percent for an individual who was on ARVs as compared to one who was not on 
ARVs. This implies that patients on ARVs tended to die faster than the ones who were not on 
ARVs. This could be that patients on ARVs are very sick and therefore their immune system is 
too low to fight opportunistic infections like Hepatitis B. It could also be a result of interaction 
between ARVs and HBV drugs which leads to toxicity in the body. Overlapping toxicity profiles 
may result in the interruption or alteration of Hepatitis B and HIV regimens with potential 
subsequent microbiological or virological failure. This finding is consistent with Dean et al. 
(2002) who found out that HIV/HBV co-infected patients on ARVs and Hepatitis B therapy 
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concomitantly were significantly more likely to suffer an adverse event leading to interruptions 
in Hepatitis B/HIV therapy. 
 
Also Moore et al. (2007) in their study found out that Hepatitis B and TB remain important cause 
of illness and death in patients receiving ART in Uganda. He noted however, that both appear to 
decline markedly, after 6 months of ART. Therefore HIV/HBV as well as HIV/TB co-infected 
patients should be entered in care early enough to prevent advance stages of Hepatitis B and TB. 
Patients who had hepatocellular carcinoma at baseline had their hazard increased by a factor of 
2.16 as compared to those who had chronic active hepatitis B (p=0.057). Those ones who had 
Cirrhosis had their hazard increased by a factor of 1.22 as compared to those who had chronic 
active hepatitis B (P=0.079). In this study, patients who had hepatocellular carcinoma were at a 
high risk of death as compared to those who had chronic active hepatitis B. Similarly patients 
who had Cirrhosis were also at a high risk of death as compared to those who had chronic active 
hepatitis B. This could be due to the fact that patients with hepatocellular carcinoma have cancer 
that is acute and it affects the liver system causing pain in the body. Therefore a patient can 
easily die if not attended to immediately. Cirrhosis affects many other parts of the body, apart 
from the liver and ascites (fluid retention in the abdominal cavity) is the most common 
complication of cirrhosis, and is associated with a poor quality of life, increased risk of infection, 
and a poor long-term outcome. Other potentially life-threatening complications are hepatic 
encephalopathy (confusion and coma) and bleeding from esophageal varices.  
 
Under normal circumstances, the disease is diagnosed late when it has reached its advanced 
stages. The diagnosis of Hepatitis B has never been easy as there is a very wide range of clinical 
features. The advent of HIV related Hepatitis B, with many unusual presenting features, has 
added significantly to the diagnostic difficulties. Therefore patients with Cirrhosis are at a higher 
risk of death due to late diagnosis or poor diagnosis of the disease. 
This is in agreement with a study that was done by Mcmahon et al. (1990) when they found out 
that Cirrhosis was independently associated with shorter survival as compared to chronic active 
hepatitis B. 
 
Patients with tertiary education had their hazard reduced by a factor of 0.66 as compared to those 
with no education after controlling for other factors (p=0.024). In this study, educated patients 
were at a reduced risk of death as compared to the uneducated ones. This could be attributed to 
the fact that educated people may have access to better treatment since they can afford medical 
expenses than the uneducated. The educated may also understand the usefulness of the treatment 
as well as having nutritious diets as compared to the uneducated. These patients should be 
encouraged to take the drugs as well as nutritional foods. 
 
5. Summary, Conclusions and Recommendations 
The main objectives of this study were to determine the socio-demographic and clinical factors 
responsible for the differentials in the survival of HIV/HBV co-infected patients. In order to 
establish the relationship between socio-demographic and clinical factors with survival, the log 
rank test was used. Education level, weight, being on ARVs and HBV related condition were 
found to have a statistically significant effect on the duration of survival. The hazard was highest 
among patients who were in the Disease stage III and lowest among the Disease stage II. A 1 
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kilogram increase in weight reduced the hazard by 4% and the hazard increase by 96% for an 
individual on ARV’s as compared to one not on ARV’s. Patients who had hepatocellular 
carcinoma and cirrhosis had increased hazards than those who had active hepatitis B. Patients 
with tertially education had their hazard reduced by 66% as compared to those who  had no 
education at all.  
 
The risk factors for death in HIV/HBV co-infected patients included being on ARVs and HBV 
related condition, weight, the level of education. HIV/HBV co-infected patients on ARVs had an 
increased death rate as compared to those who were not on ARVs.  This finding is consistent 
with Dean et al. (2002) who found out that HIV/HBV co-infected patients on ARVs and HBV 
therapy concomitantly were significantly more likely to suffer an adverse event leading to 
interruptions in HIV/HBV therapy. 
 
Patients who had Hepatocellular carcinoma or Cirrhosis at diagnosis were at an increased risk of 
death as compared to those who had chronic active hepatitis B. This is in agreement with a study 
that was done by Giovanni B Gaeta et al. (2003) when they found out Hepatocellular carcinoma 
(HCC, also called malignant hepatoma) is a primary malignancy (cancer) of the liver. Most cases 
of HCC are secondary to either a viral hepatitide infection (hepatitis B or C) or cirrhosis 
(alcoholism being the most common cause of hepatic cirrhosis), and that the usual outcome is 
poor, because only 10 - 20% of hepatocellular carcinomas can be removed completely using 
surgery. If the cancer cannot be completely removed, the disease is usually deadly within 3 to 6 
months. Increasing weight among the HIV/HBV co-infected patients was associated with longer 
survival time. Also patients who were educated had a reduced death rate as compared to the 
uneducated ones.  
 
The HBV-HIV drugs are considered very effective if a patient eats a balanced diet and comply 
with prescribed doses at the right time. Most of the educated people are working and therefore 
can afford treatment and balanced diets unlike the uneducated. Therefore, emphasis should be on 
designing Information Education Communication (IEC) materials to sensitize the uneducated 
HIV/HBV co-infected patients on effects of non compliance and unbalanced diets. Patients on 
ARVs had an increased death rate as compared to those who were not on ARVs, the explanation 
for this is that most Patients sought use of ARVs when in final stages of Hepatitis B and have 
already developed Cirrhosis which easily develops into liver cancer. This study therefore should 
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